Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 72, No. 1, 2011
Issue release date: September 2011
Section title: Original Paper
Hum Hered 2011;72:45–53

EX-HOM (EXome HOMozygosity): A Proof of Principle

Pippucci T.a · Benelli M.c, d, e · Magi A.d, e, f · Martelli P.L.b · Magini P.a · Torricelli F.d · Casadio R.b · Seri M.a · Romeo G.a
aMedical Genetics Unit, Department of Gynecological, Obstetric and Pediatric Sciences, and bLaboratory of Biocomputing, CIRB/Department of Biology, University of Bologna, Bologna, cINFN, National Institute for Nuclear Physics, Section of Florence, dDiagnostic Genetic Unit, Careggi Hospital, AOUC, eCenter for the Study of Complex Dynamics, and fDepartment of Medical and Surgical Critical Care, University of Florence, Florence, Italy
email Corresponding Author

Tommaso Pippucci

Medical Genetics Unit, Department of Gynecological, Obstetric and Pediatric Sciences

University of Bologna

IT–40138 Bologna (Italy)

Tel. +39 051 208 8387, E-Mail tommaso.pippucci@unibo.it

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Objective: We provide the proof of principle that exome sequencing of only two affected siblings born to first-cousin parents is capable of directly identifying a single candidate gene for an autosomal recessive disorder. This strategy, which we call EX-HOM (EXome HOMozygosity), combines in a single step the capacity of exome sequencing to identify all the coding variants present in a genome with the property of homozygosity mapping to limit the search for candidate genes to specific chromosomal regions. Methods: We sequenced the exomes of two siblings born to first-cousin parents affected with dysmyelinating leukodystrophy and spastic paraparesis caused by a mutation in FA2H. We used exome sequencing data to identify homozygous regions shared by the two affected siblings (EX-HOM regions), compared them with the regions of maximum LOD score obtained with SNP genotyping, and selected the candidate variants within. Results: We identified regions of shared homozygosity (>1 Mb) accounting for about 290 Mb, containing only 3 candidate variants. Among these, the FA2H mutation remained the only plausible one. Conclusion: In single consanguineous pedigrees with a few affected sibs, EX-HOM can be a one-step approach to identify the candidate genetic defect, bypassing obstacles such as genetic heterogeneity and the need for large pedigrees.

© 2011 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 24, 2011
Accepted: June 03, 2011
Published online: August 18, 2011
Issue release date: September 2011

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 2

ISSN: 0001-5652 (Print)
eISSN: 1423-0062 (Online)

For additional information: http://www.karger.com/HHE

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.